Harvard Medical School professor, Tom Stossel has made the case that active collaboration between the academy and the pharmaceutical industry is a net positive for consumers. He dives deeper into those issues in this talk from the Pacific Research Institute and the Benjamin Rush Society.
Dr. Thomas P. Stossel is a professor of medicine at Harvard Medical School. He was educated at Princeton University and Harvard Medical School. He trained in internal medicine at the Massachusetts General Hospital and in hematology at Boston Children's and Peter Bent Brigham Hospitals. He was head of Hematology and Oncology at Massachusetts General Hospital from 1976 until 1991, was Co-Director of the Hematology Division at Brigham & Women's Hospital through 2006, and is currently Director of a new Division of Translational Medicine. From 1976-1980 he was a consultant to the U.S. Department of State, investigating effects of microwaves on U.S. Embassy personnel in Moscow.
Stossel's basic research concerns fundamental mechanisms of cell motility. This research led to discoveries that may reduce critical care complications of major injury and impact platelet transfusion therapy. His policy interests concern physician and researcher interactions with private industry. He was President of the American Society for Clinical Investigation and Editor in Chief of its Journal of Clinical Investigation and served as President of the American Society of Hematology, for which he received its Dameshek and Thomas Awards. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Institute of Medicine. He is Editor in Chief of Current Opinion in Hematology, a member of the Lasker Awards Jury, a member of the Board of Directors of Zymequest Corporation, and a founding scientist of Critical Biologics Corporation. He has been awarded honorary M.D. degrees from the Universities of Linkoping (Sweden) and Geneva (Switzerland).
"Claims that commercialism degrades research, education, public trust, and hurts patients are false," insists doctor Tom Stossel, director of translational medicine at the Brigham & Women's Hospital. Stossel argues that conflict of interest is overblown, and regulation has high cost and few benefits for medicine.